penbutolol Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
beta-adrenoreceptor antagonists 2078 38363-40-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • penbutolol
  • penbutolol sulfate
  • betapressin
  • levopenbutolol
A nonselective beta-blocker used as an antihypertensive and an antianginal agent.
  • Molecular weight: 291.44
  • Formula: C18H29NO2
  • CLOGP: 3.64
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 2
  • TPSA: 41.49
  • ALOGS: -4.14
  • ROTB: 7

  • Status: OFM

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
40 mg O

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 3.92 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Hosey CM, Chan R, Benet LZ
BA (Bioavailability) 93 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Dec. 30, 1987 FDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

SourceCodeDescription
ATC C07AA23 CARDIOVASCULAR SYSTEM
BETA BLOCKING AGENTS
BETA BLOCKING AGENTS
Beta blocking agents, non-selective
ATC C07CA23 CARDIOVASCULAR SYSTEM
BETA BLOCKING AGENTS
BETA BLOCKING AGENTS AND OTHER DIURETICS
Beta blocking agents, non-selective, and other diuretics
FDA MoA N0000000161 Adrenergic beta-Antagonists
FDA EPC N0000175556 beta-Adrenergic Blocker
MeSH PA D018663 Adrenergic Agents
MeSH PA D018674 Adrenergic Antagonists
MeSH PA D000319 Adrenergic beta-Antagonists
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D018377 Neurotransmitter Agents
CHEBI has role CHEBI:35530 beta-adrenoceptor antagonists

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Angina pectoris off-label use 194828000
Bronchospasm contraindication 4386001
Complete atrioventricular block contraindication 27885002
Depressive disorder contraindication 35489007
Anaphylaxis contraindication 39579001
Sinus bradycardia contraindication 49710005
Diabetes mellitus contraindication 73211009 DOID:9351
Pulmonary emphysema contraindication 87433001
Cardiogenic shock contraindication 89138009
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Partial atrioventricular block contraindication 195039008
Decompensated cardiac failure contraindication 195111005
Disease of liver contraindication 235856003 DOID:409
Raynaud's phenomenon contraindication 266261006
Pregnancy, function contraindication 289908002
Severe chronic obstructive pulmonary disease contraindication 313299006
Right ventricular failure contraindication 367363000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.31 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Beta-2 adrenergic receptor GPCR ANTAGONIST Ki 9 WOMBAT-PK CHEMBL
Beta-1 adrenergic receptor GPCR ANTAGONIST Ki 8.80 WOMBAT-PK CHEMBL
Alpha-1-acid glycoprotein 1 Secreted WOMBAT-PK
5-hydroxytryptamine receptor 1A GPCR Ki 7.92 WOMBAT-PK
5-hydroxytryptamine receptor 1A GPCR Ki 8.62 CHEMBL

External reference:

IDSource
4019879 VUID
N0000147964 NUI
D00602 KEGG_DRUG
38363-32-5 SECONDARY_CAS_RN
4019466 VANDF
4019879 VANDF
C0005317 UMLSCUI
CHEBI:7954 CHEBI
CHEMBL2361370 ChEMBL_ID
CHEMBL1290 ChEMBL_ID
CHEMBL1200363 ChEMBL_ID
D010394 MESH_DESCRIPTOR_UI
DB01359 DRUGBANK_ID
37464 PUBCHEM_CID
7263 IUPHAR_LIGAND_ID
3017 INN_ID
78W62V43DY UNII
7973 RXNORM
5241 MMSL
d00332 MMSL
001862 NDDF
004746 NDDF
108542009 SNOMEDCT_US
372505004 SNOMEDCT_US
386865000 SNOMEDCT_US

Pharmaceutical products:

None